EGFR and mucopolysaccharidosis type 3B: These findings demonstrate that the specific EGFR inhibition with AG1478 reduces both hypertrophy and lysosomal defects in our MPS IIIB cell model, providing more evidence for the involvement of EGFR activation in the development of cell pathology in MPS IIIB disease.